LEUKOCYTE-ENDOTHELIAL CELL ADHESION IN TUMOR IMMUNITY
LEUKOCYTE-ENDOTHELIAL CELL ADHESION IN TUMOR IMMUNITY
批准号:
6050909
负责人:
Sharon S Evans
金额:
$19.97万
依托单位国家:
美国
项目类别:
财政年份:
1999
资助国家:
美国
项目状态:
已结题
起止时间:
1999-12-13 至 2002-11-30
关键词:
T cell receptor antineoplastics biological signal transduction cell adhesion cytotoxic T lymphocyte disease /disorder model genetically modified animals hyperthermia therapy immunocytochemistry integrins interleukin 6 laboratory mouse leukocytes lymph nodes monoclonal antibody natural killer cells neoplasm /cancer immunology neoplastic cell neoplastic process pancreatic islet neoplasm protein structure function receptor expression selectins tissue /cell culture vascular endothelium
中文摘要
这项建议解决了核心假设,即通过使用发热范围加温刺激L-选择素和α-4beta7整合素依赖的免疫效应细胞向恶性肿瘤组织和肿瘤引流淋巴结募集免疫效应细胞,可以实现显著的抗肿瘤反应。这一假说是基于新的信息提出的,该信息表明,在RIP-Tag5转基因小鼠模型中,发热范围、持续时间长的全身热疗可刺激肿瘤血管上两种白细胞归巢受体L-选择素和α4β7整合素的内皮配体的表达。这一发现与胰岛肿瘤中淋巴细胞浸润增加有关。值得注意的是,在RIP-Tag5小鼠中,由于SV40T抗原(Tag)转基因表达而发展起来的胰腺肿瘤通常没有浸润性淋巴细胞。现提出三种独立的方法来解决这一中心假设:(1)旨在研究L-选择素和α4beta7整合素在靶向免疫效应细胞方面的直接作用,在RIP-Tag5单转基因小鼠和RIP-Tag5双转基因小鼠中,由于B7.1共刺激分子或标签特异性T细胞受体的共表达而导致高频率的肿瘤反应性细胞毒性T淋巴细胞。黏附分子在淋巴细胞募集中的具体作用将通过抗体阻断研究和使用通过L-选择素或α4β7整合素与内皮限制性结合的细胞系来描述。(2)我们将在细胞系中利用体外激酶分析和显性阴性方法研究高温控制淋巴细胞-内皮细胞黏附的分子机制,以研究特定的信号转导通路(即MAPK、HSP90、JAK/STATS、Src激酶和IL-6)的参与。(3)研究的目的是确定发热范围的WBH联合细胞因子(干扰素-α、IL-2)是否通过促进L-选择素和/或α-4beta7整合素依赖的CTL在胰岛肿瘤中的积聚来抑制RIP-Tag转基因小鼠的肿瘤进展。WBH对产生Th1细胞因子(例如,干扰素-γ)的免疫细胞在肿瘤内定位的影响也将被检测,因为这些细胞因子是产生细胞介导的肿瘤免疫的基础。预计拟议的研究将为未来评估发热范围内的WBH作为辅助治疗癌症的有效性提供一个框架,并结合旨在增强肿瘤特异性CTL生成的免疫疗法。
英文摘要
This proposal addresses the central hypothesis that significant antitumor responses can be achieved through the use of fever- range hyperthermia to stimulate L-selectin and alpha4beta7 integrin-dependent recruitment of immune effector cells to malignant tissues and tumor-draining lymph nodes. The hypothesis is formulated on the basis of new information demonstrating that fever range, long duration whole body hyperthermia (WBH) stimulates expression of endothelial ligands for two leukocyte homing receptors, L-selectin and alpha4beta7 integrin, on tumor vessels in the RIP-Tag5 transgenic mouse model. This finding is correlated with increased lymphocyte infiltration into beta islet tumors. Notably, pancreatic tumors that develop as a result of transgene expression of the SV40 T antigen (Tag) in RIP-Tag5 mice are normally devoid of infiltrating lymphocytes. Three independent approaches are proposed to address the central hypothesis: (1) Strategies are designed to examine the direct role of L-selectin and alpha4beta7 integrin in targeting immune effector cells to pancreatic beta islet tumors in response to fever-range WBH in RIP-Tag5 single transgenic mice and in RIP- Tag5 double transgenic mice that have a high frequency of tumor- reactive cytotoxic T lymphocytes (CTL) as a result of coexpression of the B7.1 costimulatory molecule or a Tag-specific T cell receptor. The specific role of adhesion molecules in lymphocyte recruitment will be delineated by antibody blockade studies and using cell lines that restrictively bind to endothelium via L-selectin or alpha4beta7 integrin. (2) The molecular mechanisms underlying hyperthermia control of lymphocyte-endothelial adhesion will be investigated in cell lines using in vitro kinase assays and dominant negative approaches to examine the involvement of specific signal transduction pathways (i.e., MAPK, HSP90, JAK/STATs, Src kinases, and IL-6). (3) Studies are designed to determine if fever-range WBH, in combination with cytokines (IFN-alpha, IL-2), inhibits tumor progression in RIP-Tag transgenic mice by enhancing L- selectin and/or alpha4beta7 integrin-dependent accumulation of CTL in beta islet tumors. WBH effects on intratumoral localization of immune cells that produce Th1-cytokines (e.g., IFN-gamma) will also be examined since these cytokines are fundamental to the generation of cell-mediated tumor immunity. The proposed studies are expected to provide a framework for future evaluation of the efficacy of fever-range WBH as an adjuvant in the treatment of cancer in combination with immunotherapies designed to enhance the generation of tumor- specific CTL.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Inflammatory Control of Lymphocyte Trafficking
-
批准号:8005710
-
项目类别:
-
资助金额:$46.71万
-
财政年份:2010
-
负责人:Sharon S Evans
-
依托单位:
Inflammatory Control of Lymphocyte Trafficking
-
批准号:7789702
-
项目类别:
-
资助金额:$46.53万
-
财政年份:2010
-
负责人:Sharon S Evans
-
依托单位:
Inflammatory Control of Lymphocyte Trafficking
-
批准号:8602800
-
项目类别:
-
资助金额:$48.74万
-
财政年份:2010
-
负责人:Sharon S Evans
-
依托单位:
Inflammatory Control of Lymphocyte Trafficking
-
批准号:8204839
-
项目类别:
-
资助金额:$47.37万
-
财政年份:2010
-
负责人:Sharon S Evans
-
依托单位:
Inflammatory Control of Lymphocyte Trafficking
-
批准号:8414884
-
项目类别:
-
资助金额:$45.16万
-
财政年份:2010
-
负责人:Sharon S Evans
-
依托单位:
Inflammatory Control of Lymphocyte Trafficking
-
批准号:7847761
-
项目类别:
-
资助金额:$25.61万
-
财政年份:2009
-
负责人:Sharon S Evans
-
依托单位:
LEUKOCYTE-ENDOTHELIAL CELL ADHESION IN TUMOR IMMUNITY
-
批准号:6475826
-
项目类别:
-
资助金额:$20.75万
-
财政年份:1999
-
负责人:Sharon S Evans
-
依托单位:
Leukocyte-Endothelial Adhesion in Tumor Immunity
-
批准号:7742977
-
项目类别:
-
资助金额:$31.16万
-
财政年份:1999
-
负责人:Sharon S Evans
-
依托单位:
Leukocyte-Endothelial Adhesion in Tumor Immunity
-
批准号:8196824
-
项目类别:
-
资助金额:$31.5万
-
财政年份:1999
-
负责人:Sharon S Evans
-
依托单位:
Leukocyte-Endothelial Adhesion in Tumor Immunity
-
批准号:6749014
-
项目类别:
-
资助金额:$32.72万
-
财政年份:1999
-
负责人:Sharon S Evans
-
依托单位:
Leukocyte-Endothelial Adhesion in Tumor Immunity
-
批准号:6885338
-
项目类别:
-
资助金额:$33.17万
-
财政年份:1999
-
负责人:Sharon S Evans
-
依托单位:
Leukocyte-Endothelial Adhesion in Tumor Immunity
-
批准号:7232653
-
项目类别:
-
资助金额:$32.36万
-
财政年份:1999
-
负责人:Sharon S Evans
-
依托单位:
Leukocyte-Endothelial Adhesion in Tumor Immunity
-
批准号:7992438
-
项目类别:
-
资助金额:$31.06万
-
财政年份:1999
-
负责人:Sharon S Evans
-
依托单位:
Leukocyte-Endothelial Adhesion in Tumor Immunity
-
批准号:6681978
-
项目类别:
-
资助金额:$32.27万
-
财政年份:1999
-
负责人:Sharon S Evans
-
依托单位:
Leukocyte-Endothelial Adhesion in Tumor Immunity
-
批准号:7062429
-
项目类别:
-
资助金额:$32.85万
-
财政年份:1999
-
负责人:Sharon S Evans
-
依托单位:
Leukocyte-Endothelial Adhesion in Tumor Immunity
-
批准号:7584704
-
项目类别:
-
资助金额:$31.16万
-
财政年份:1999
-
负责人:Sharon S Evans
-
依托单位:
LEUKOCYTE-ENDOTHELIAL CELL ADHESION IN TUMOR IMMUNITY
-
批准号:6329055
-
项目类别:
-
资助金额:$20.15万
-
财政年份:1999
-
负责人:Sharon S Evans
-
依托单位:
Leukocyte-Endothelial Adhesion in Tumor Immunity
-
批准号:8387717
-
项目类别:
-
资助金额:$30.03万
-
财政年份:1999
-
负责人:Sharon S Evans
-
依托单位:
XENOGENEIC MODEL FOR HOMING OF HUMAN LYMPHOCYTES
-
批准号:2284182
-
项目类别:
-
资助金额:$3.31万
-
财政年份:1993
-
负责人:Sharon S Evans
-
依托单位:
ROLE OF A-INTERFERON RECEPTOR IN HUMAN IMMUNOREGULATION
-
批准号:3458680
-
项目类别:
-
资助金额:$6.26万
-
财政年份:1988
-
负责人:Sharon S Evans
-
依托单位:
海外基金